Drug Profile
Research programme: therapeutic agents - AstraZeneca/Jubilant Biosys
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Jubilant Biosys
- Developer AstraZeneca; Jubilant Biosys
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Cognition disorders; Metabolic disorders; Neurological disorders; Pain; Psychiatric disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cardiovascular-disorders in Unknown
- 04 Nov 2017 No recent reports of development identified for research development in Cognition-disorders in Unknown
- 04 Nov 2017 No recent reports of development identified for research development in Metabolic-disorders in Unknown